share_log

LadRx (NASDAQ:CYTR) Now Covered by Analysts at StockNews.com

Defense World ·  Dec 15, 2022 03:51

Stock analysts at StockNews.com began coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a note issued to investors on Thursday. The brokerage set a "hold" rating on the stock.

LadRx Stock Up ∞

Shares of NASDAQ:CYTR opened at $0.09 on Thursday. LadRx has a 12-month low of $0.05 and a 12-month high of $0.86.

Get LadRx alerts:

About LadRx

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

Featured Articles

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • Is Enterprise Products Partners Fairly Valued?
  • Will WhatsApp Partnership Boost MercadoLibre's Earnings?
  • 3 Mid-Caps That Could Double in 2023
  • Mullen Automotive Shares Jump After Signing New Partner
  • REV Group Leads Specialty Vehicle Manufacturers Higher

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment